SCI Pharmtech, Inc. (TPE:4119)

Market Cap	5.80B
Revenue (ttm)	1.39B
Net Income (ttm)	115.35M
Shares Out	119.51M
EPS (ttm)	0.96
PE Ratio	50.50
Forward PE	n/a
Dividend	1.50 (3.08%)
Ex-Dividend Date	Jul 1, 2025

Volume	74,947
Average Volume	105,865
Open	48.70
Previous Close	48.70
Day's Range	48.25 - 49.10
52-Week Range	46.85 - 91.30
Beta	-0.10
RSI	43.27
Earnings Date	Mar 19, 2026

About SCI Pharmtech

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2024, SCI Pharmtech's revenue was 1.52 billion, an increase of 26.54% compared to the previous year's 1.20 billion. Earnings were 534.68 million, an increase of 81.42%.